Skip to main content
OpenTrials
Completed

NCT Number: NCT01987999

Eradication of Prostate Cancer Using F-989

The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of prostate cancer
  • Referred to the study by their treating physician

Exclusion criteria

  • Any type of treatment before starting study

Treatment and study plan

Acetogenins

Dietary Supplement

Primary outcomes

  1. Gleason Score

    Time frame: 1 year

    A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.

Secondary outcomes

  1. Prostate Specific Antigens (PSA)

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Optimal Health Research

Other

Registry information

Official study title

Phase II Eradication of Prostate Cancer Using F-989

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Nov 20, 2013
Registry last updated
Sep 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.